We are delighted to share with you our Trustee Report and Financial Statements for 2022. The report highlights our successes over 2022, such as our post-COVID Congress in Athens, where President Werner Seeger's committee curated an exceptional scientific programme, leaving a lasting impact.
2022 saw the departures of our CEO Stephanie Barwick and founding member Stuart Rich who were honoured for their instrumental contributions. Webinars and the monthly Community Call flourished, promoting knowledge-sharing. The regional Task Forces resumed face-to-face scientific meetings, while the specialism Task Forces continued to collaborate, convene meetings, organise webinars, and publish papers on vital issues in pulmonary vascular disease. The IDDI workstreams published research, position papers, and developed two global surveys aiming to improve access to pulmonary hypertension diagnosis and care.
Our commitment to collaboration and inclusiveness was evident as numerous speakers, moderators, panellists, and volunteers contributed to producing high-quality scientific work. PVRI GoDeep, the deep phenotyping meta-registry, brought pride with its growth and potential to inform real-life medicine through large datasets.
As we welcomed Kurt Stenmark as our new President, we embraced a future empowered by a strong global network of 10,000 friends and colleagues all dedicated to combatting pulmonary hypertension worldwide.